Document:

Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

This subscription agreement (this “Subscription Agreement”) is made as of April 19, 2017, by and among the Investors identified on the signature pages hereto (each an “Investor” and together “Investors”), and Edge Therapeutics, Inc., a Delaware corporation (the “Company”), and the parties hereto agree as follows:

1.       Subscription

(a)       The Company has authorized the sale and issuance to the Investors of up to an aggregate of 1,800,000 shares of common stock (each, a “Share” and collectively, the “Shares”), par value $0.00033 per share, for a purchase price of $10.00 per Share (the “Purchase Price”).

(b)       The offering and sale of the Shares (the “Offering”) is being made pursuant to (i) an effective Registration Statement on Form S-3 (File No. 333-214196), as such Registration Statement may be amended and supplemented from time to time (including pursuant to Rule 462(b) of the Securities Act (as defined in Section 2(b) below) (the “Registration Statement”), filed by the Company with the Securities and Exchange Commission (the “Commission”), including the prospectus contained therein dated November 2, 2016 (the “Base Prospectus”); (ii) if applicable, certain “free writing prospectuses” (as that term is defined in Rule 405 under the Securities Act (as defined below)) that have been or will be filed, if required, with the Commission and delivered to the Investors on or before the date hereof, containing certain supplemental information regarding the terms of the Offering and the Company; and (iii) a Prospectus Supplement (the “Prospectus Supplement” and together with the Base Prospectus, the “Prospectus”) containing certain supplemental information regarding the Shares and the terms of the Offering and information that may be material to the Company and its securities that was delivered to the Investors and will be filed with the Commission. The Prospectus, together with the documents incorporated by reference therein, are collectively referred to herein as the “Disclosure Package.”

(c)       The Investors agree to purchase from the Company the number of Shares set forth on the signature pages hereto for the aggregate Purchase Price set forth below on the signature pages hereto on or before 5:00 p.m. Eastern Time on April 19, 2017 (the “Commitment Date”), otherwise the Company shall have the option to terminate this Subscription Agreement.

(d)       At the Closing (as defined in Section 2(a) below), the Company and the Investors agree that the Investors will purchase from the Company and the Company will issue and sell to the Investors, upon the terms and conditions set forth herein, the number of Shares set forth on the signature pages hereto for the aggregate Purchase Price set forth on the signature pages hereto. The Investors acknowledge that the Offering is not being underwritten and that there is no minimum offering amount.

(e)       This Subscription Agreement will involve no obligation or commitment of any kind until this Subscription Agreement is accepted and countersigned by or on behalf of the Company.

2.       Closing and Delivery of the Shares and Funds.

(a)       The completion of the purchase and sale of the Shares (the “Closing”) shall take place at the offices of Dechert LLP, 1095 Avenue of the America, New York, NY 10036 or such other location as the parties shall mutually agree on April 21, 2017, or at such other time and location as the Company and the Investors shall agree (the “Closing Date”).  At the Closing, (a) the Company shall cause the Company’s transfer agent to deliver to each Investor, via electronic book-entry in accordance with the instructions provided by such Investor on the signature pages hereto, the number of Shares set forth on the signature pages hereto, registered in the name of such Investor and (b) the aggregate Purchase Price for the Shares as set forth on the signature pages hereto will be delivered by or on behalf of such Investor to the Company.

(b)       The Company’s obligation to issue and sell the Shares to the Investors and each Investor’s obligation to purchase the Shares from the Company shall be subject to: (x) no stop order suspending the effectiveness of the Registration Statement or any part thereof, or preventing or suspending the use of the Base Prospectus or the Prospectus or any part thereof, shall have been issued and no proceedings for that purpose or pursuant to Section 8A under the Securities Act of 1933, as amended (the “Securities Act”), shall have been initiated or threatened by the Commission and (y) the Financial Industry Regulatory Authority shall have raised no objection to the fairness and reasonableness of the arrangements made by the Company with Maxim Group LLC.

 

3.       Representations, Warranties and Covenants of the Company. The Company acknowledges, represents and warrants to, and agrees with, the Investors that:

(a)       The Company has the requisite right, power and authority to enter into this Subscription Agreement, to authorize, issue and sell the Shares as contemplated by this Subscription Agreement and to perform and to discharge its obligations hereunder; and this Subscription Agreement has been duly authorized, executed and delivered by the Company, and constitutes the valid and binding obligation of the Company enforceable in accordance with its terms, except (i) as may be limited by bankruptcy, insolvency, reorganization or other similar laws relating to enforcement of creditors’ rights generally and by general principles of equity and (ii) to the extent any indemnification or contribution provisions contained therein may further be limited by applicable laws and principles of public policy.

(b)       The Shares to be issued and sold by the Company to the Investors under this Subscription Agreement have been duly authorized and the Shares, when issued and delivered against payment therefor as provided in this Subscription Agreement, will be validly issued, fully paid and non-assessable and free of any preemptive or similar rights. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, proposes to file the Prospectus with the Commission pursuant to Rule 424(b) in relation to the sale of the Shares.  Other than with respect to discussions regarding the Offering, the Company does not believe that it has provided any confidential or proprietary information of the Company to the Investors or any of their directors, officers, employees, agents or advisors.

(c) The execution and delivery of this Subscription Agreement and the consummation of the transactions contemplated hereby will not (i) result in a breach or violation of any of the terms and provisions of, or constitute a default under, any law, rule or regulation to which the Company or any subsidiary is subject, or by which any property or asset of the Company or any subsidiary is bound or affected, (ii) conflict with, result in any violation or breach of, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, lease, credit facility, debt, note, bond, mortgage, indenture or other instrument or obligation or other understanding to which the Company or any subsidiary is a party of by which any property or asset of the Company or any subsidiary is bound or affected, or (iii) result in a breach or violation of any of the terms and provisions of, or constitute a default under, the Company’s certificate of incorporation, except in the case of clauses (i) and (ii) such breaches, violations, defaults, or conflicts which are not, individually or in the aggregate, reasonably likely to result in a material adverse effect upon the business, properties, operations, condition (financial or otherwise) or results of operations of the Company and its subsidiaries, taken as a whole, or in its ability to perform its obligations under the Subscription Agreement.

(d)       The Company shall, by 5:00 p.m. on the trading day immediately following the date of pricing of the Offering, issue a press release disclosing the material terms of the Offering, and issue a Current Report on Form 8-K including the form of subscription agreement and an opinion of legal counsel as to the validity of the Shares as exhibits thereto. The Company agrees that neither the press release nor the Current Report on Form 8-K will contain the identity of the Investors, unless agreed to by the Investors or otherwise required by law or any regulatory agency that regulates the Company.

(e)          Except as set forth in the Prospectus Supplement, no brokerage or finder’s fees or commissions are or will be payable by the Company or any of its subsidiaries to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with respect to the transactions contemplated by the Agreement. The Investors shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this section that may be due in connection with the transactions contemplated by the Agreement.

 

4.       Representations, Warranties and Covenants of the Investors. Each Investor acknowledges, represents and warrants to, and agrees with, the Company that:

(a)          At the time the Investor was offered the Shares, it was, and as of the date hereof it is, either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act, (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act or (iii) a trust or other entity for which Muneer A. Satter serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over the Shares to be purchased by such trust or other entity.

(b)          It has had the opportunity to review the Subscription Agreement (including all exhibits and schedules thereto) and the Company’s filings with the Commission and has been afforded the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares.

(c)       (i) If the Investor is outside the United States, it will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Shares or has in its possession or distributes any offering material, in all cases at its own expense and (ii) no agent of the Company has been authorized to make and no such agent has made any representation, disclosure or use of any information in connection with the issue, placement, purchase and sale of the Shares, except as set forth in or incorporated by reference in the Base Prospectus or the Prospectus Supplement or as otherwise contemplated by this Subscription Agreement.

(d)       (i) The Investor has full right, power, authority and capacity to enter into this Subscription Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Subscription Agreement, and (ii) this Subscription Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms, except (a) as may be limited by bankruptcy, insolvency, reorganization or other similar laws relating to enforcement of creditors’ rights generally and by general principles of equity and (b) to the extent any indemnification or contribution provisions contained therein may further be limited by applicable laws and principles of public policy.

(e)       The Shares to be purchased by the Investor hereunder will be acquired for the Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to the Investor’s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable federal and state securities laws. If the Investor is an affiliate of the Company (within the meaning of Rule 144 promulgated under the Securities Act), the Investor acknowledges and understands that the Shares may not be resold by the Investor unless such resale is registered under the Securities Act or such resale is effected pursuant to a valid exemption from the registration requirements of the Securities Act.

(f)          Nothing in this Subscription Agreement, the Prospectus, the Disclosure Package or any other materials presented to the Investor in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares.

(g)       The Investor has not directly or indirectly, nor has any person acting on behalf of or pursuant to any understanding with the Investor, disclosed any information regarding the Offering to any third parties (other than its legal, accounting and other advisors) or engaged in any transactions in the securities of the Company (including, without limitations, any short sales (as defined in Rule 200(a) of Regulation SHO) involving the Company’s securities). The Investor covenants that neither it nor any person acting on its behalf or pursuant to any understanding with it will engage in any transactions in the securities of the Company (including short sales) prior to the time that the transactions contemplated by this Subscription Agreement are publicly disclosed.

(h)       The Investor’s signature page sets forth all securities of the Company held or beneficially owned by such Investor as of the date hereof. Such Investor does not hold or beneficially own any other securities of the Company, except as indicated on the signature page hereto.

 

5.       Miscellaneous.

(a)       Entire Agreement; Modifications. Except as otherwise provided herein, this Subscription Agreement constitutes the entire understanding and agreement between the parties with respect to its subject matter and there are no agreements or understandings with respect to the subject matter hereof which are not contained in this Subscription Agreement. This Subscription Agreement may be modified only in writing signed by the signed by the Company and the Investors.

(b)       Survival. All representations, warranties, and agreements of the Company and the Investors herein shall survive delivery of, and payment for, the Shares purchased hereunder.

(c)       Counterparts. This Subscription Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and shall become effective when counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties need not sign the same counterpart. Execution may be made by delivery of a facsimile or PDF.

(d)       Severability. The provisions of this Subscription Agreement are severable and, in the event that any court or officials of any regulatory agency of competent jurisdiction shall determine that any one or more of the provisions or part of the provisions contained in this Subscription Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of this Subscription Agreement and this Subscription Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to the maximum extent possible, so long as such construction does not materially adversely affect the economic rights of either party hereto.

(e)       Notices. All notices or other communications required or permitted to be provided hereunder shall be in writing and shall be deemed effectively given (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed e-mail or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company or the Investors, as applicable, at the address for such recipient listed on the signature pages hereto or at such other address as such recipient has designated by two days advance written notice to the other parties hereto.

(f)       Governing Law. This Subscription Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware without regard to the choice of law principles thereof.

(f)       WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

(g)          Headings. The headings of the various sections of this Subscription Agreement have been inserted for convenience of reference only and will not be deemed to be part of this Subscription Agreement.

(h)       Confirmation of Sale. Each Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Subscription Agreement shall constitute written confirmation of the Company’s acceptance and agreement to sell the applicable Shares to such Investor.

(i)          Fees and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Subscription Agreement. The Company shall pay all transfer agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by the Investors), stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the Investors.

 

(j)          Termination. This Subscription Agreement may be terminated by the Investors, by written notice to the Company, if the Closing has not been consummated on or before the Closing Date; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party.

[Signature pages follow]

 

IN WITNESS WHEREOF, the parties hereto have executed this Subscription Agreement effective as of the date first written above.

 

	 	
EDGE THERAPEUTICS, INC.

	 
	 	 	 	 
	 	
By:

	 	 
	 	
Name:

	 	 
	 	
Title: 

	 	 
	 	 	 	 
	 	
Address for notice:

	 
	 	 	 
	 	
Edge Therapeutics, Inc.

	 
	 	
300 Connell Drive, Suite 4000

	 
	 	
Berkeley Heights, NJ 07922

	 
	 	
Attention: Chief Financial Officer

	 
	 	
Email: bmarchio@edgetherapeutics.com

	 
	 	
Facsimile: 908-790-1212

	 
	 	 	 
	 	
With copies to:

 

Edge Therapeutics, Inc.

300 Connell Drive, Suite 4000

Berkeley Heights, NJ 07922

Attention: General Counsel

Email: bmiddlekauff@edgetherapeutics.com

Facsimile: 908-790-1212

	 
	 	 	 
	 	
Dechert LLP

	 
	 	
1095 Avenue of the Americas

	 
	 	
New York, NY 10036

	 
	 	
Attention: David Rosenthal

	 
	 	
E-mail: david.rosenthal@dechert.com

	 
	 	
Facsimile: (212) 698-0416

	 

[Signature Page to Subscription Agreement]

 

	 	
INVESTOR:

	 
	 	 	 
	 	 	 	 
	 	
(Print Name of Investor)

	 
	 	 	 	 
	 	
By:

	 	 
	 	
Name:

	 	 
	 	
Title:

	 	 
	 	 	 	 
	 	
Address for notice:

	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	
Email:

	 	 
	 	 	 	 
	 	
Facsimile:

	 	 

Number of Shares: _____________________________________

Purchase Price Per Share: $_____

Aggregate Purchase Price: _____________________________________

Employer Identification or Social Security Number: _______________________

Company Shares currently held by Investor: ____________________________

DWAC Delivery instructions for the Shares:

	
Name of DTC Participant (broker-dealer at which the account or accounts to be credited with the Shares are maintained):

	 

DTC Participant Number: _________________________

	
Name of Account at DTC Participant being credited with the Shares:

	 

Account Number at DTC Participant being credited with the Shares:  ________________________________

[Signature Page to Subscription Agreement]Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as
of April 10, 2017, is entered into by and between IMMUNE PHARMACEUTICALS,
INC., a Delaware corporation (the “Company”), and EMA
Financial, LLC, a Delaware limited liability company (the “Purchaser”).

 

WHEREAS, subject to the
terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the
“Securities Act” or “1933 Act”), and Rule 506 promulgated thereunder by the United States Securities and
Exchange Commission (the “SEC”), the Company desires to issue and sell to the Purchaser, and the Purchaser desires
to purchase from the Company (i) a 6% Convertible Note of the Company, in the form attached hereto as Exhibit A, in the original
principal amount of $500,000.00 (together with any note(s) issued in replacement thereof or as interest thereon or otherwise with
respect thereto in accordance with the terms thereof, the “Note”), convertible into shares (“Conversion Shares”)
of common stock, $0.001 par value per share (the “Common Stock”), of the Company, upon the terms and subject to the
limitations and conditions set forth in such Note, and (ii) a Common Stock Purchase Warrant (“Warrant”), in the form
attached hereto as Exhibit B, entitling the holder thereof to purchase 1,666,667 shares of Common Stock in accordance with the
terms hereof (“Warrant Shares”, and together with the Note, Conversion Shares and Warrant Shares, the “Securities”).

 

NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

1.          Purchase
and Sale of Note.

 

a)          Purchase
of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Purchaser, and the Purchaser agrees
to purchase from the Company, the Note and Warrant for an aggregate purchase price of $450,000.00 (“Purchase Price”).

 

b)          Form
of Payment. On the Closing Date (i) the Purchaser shall pay the Purchase Price by wire transfer of immediately available funds
to the Company, in accordance with the Company’s written wiring instructions, simultaneously with delivery of the Note, and
(ii) the Company shall deliver such Note duly executed on behalf of the Company to the Purchaser, simultaneously with delivery
of such Purchase Price.

 

c)          Closing
Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 8 and Section 9 below,
the closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the first business day
following the date hereof or such other mutually agreed upon time (the “Closing Date”) at the offices of Purchaser’s
counsel.

 

2.          Purchaser’s
Representations and Warranties. The Purchaser represents and warrants to the Company that:

 

    	 	1	 

     

    

 

a)          Investment
Purpose. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities
for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation
of applicable securities laws; provided, however, by making the representations herein, Purchaser does not agree, or make any representation
or warranty, to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities
at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. The Purchaser is acquiring
the Securities hereunder in the ordinary course of its business. The Purchaser does not presently have any agreement or understanding,
directly or indirectly, with any person to distribute any of the Securities in violation of applicable securities laws.

 

b)          Accredited
Investor Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises the Warrant or converts the Note it will be an “accredited investor” as defined in Rule
501(a) under the Securities Act.

 

c)          Reliance
on Exemptions. The Purchaser understands that the Securities are being offered and sold to it in reliance upon specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility
of the Purchaser to acquire the Securities.

 

d)          Information.
The Purchaser and its advisors, if any, have been, and for so long as the Securities remain outstanding will continue to be, furnished
with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale
of the Note and Warrant which have been reasonably requested by the Purchaser or its advisors, provided that the Purchaser has
not been furnished with, and the Company shall not in the future deliver to the Purchaser without its consent, any material non-public
information concerning the Company. The Purchaser and its advisors, if any, have been, and for so long as the Note and Warrant
remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Neither such inquiries nor any
other due diligence investigation conducted by Purchaser or any of its advisors or representatives shall modify, amend or affect
Purchaser’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Purchaser
understands that its investment in the Securities involves a significant degree of risk.

 

e)          Governmental
Review. The Purchaser understands that no United States federal or state agency or any other government or governmental agency
has passed upon or made any recommendation or endorsement of the Securities.

 

    	 	2	 

     

    

 

f)          Transfer
or Re-sale. The Purchaser understands that (i) the sale or re-sale of the Securities has not been and is not being registered
under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities
are sold pursuant to an effective registration statement under the 1933 Act, (b) the Purchaser shall have delivered to the Company
an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to
the effect that the securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration,
which opinion shall be reasonably acceptable to the Company, (c) the Securities are sold or transferred to an “affiliate”
(as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”) of the Purchaser who agrees
to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the
Securities are sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor
rule) (“Regulation S”) and the Purchaser shall have delivered to the Company an opinion of counsel reasonably acceptable
to the Company relating to such Regulation S; and (ii) any sale of such Securities made in reliance on Rule 144 may be made only
in accordance with the terms of such Rule and further, if such Rule is not applicable, any re-sale of such Securities under circumstances
in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in
the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder.
Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in
connection with a bona fide margin account or other lending arrangement.

 

g)          Legends.
The Purchaser understands that the Securities have been issued (or will be issued in the
case of the Conversion Shares) pursuant to an exemption from registration or qualification under the 1933 Act and applicable state
securities laws, and except as set forth below, the Securities shall bear any legend as required by the “blue sky”
laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against
transfer of such stock certificates):  

 

“[NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE]
[EXERCISABLE] HAVE BEEN] [THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE
COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN AGREEMENT
WITH A BROKER-DEALER OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

    	 	3	 

     

    

 

The legend set forth above
shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped
during any period when such (a) such Securities are registered for sale under an effective registration statement filed under the
1933 Act, (b) following any sale of such Securities pursuant to Rule 144, (iii) if such Securities are eligible for sale under
Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144
as to such Securities and without volume or manner-of-sale restrictions, or (iv) if such legend is not required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission).
The Company agrees, at its expense, to cause its counsel to issue a legal opinion, or to accept the opinion of counsel to the holder,
in the form, substance and scope customary for opinions of counsel in comparable transactions, to the Transfer Agent if required
by the Transfer Agent to effect the removal of the legend hereunder. The Purchaser agrees to sell all Securities, including those
represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements,
if any.

 

h)          Authorization;
Enforcement. The Purchaser is an entity duly incorporated or formed, validly existing and in good standing under the laws of
the jurisdiction of its incorporation or formation with full right, power and authority to enter into and to consummate the transactions
contemplated hereunder. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered
on behalf of the Purchaser, and this Agreement constitutes a valid and binding agreement of the Purchaser enforceable in accordance
with its terms.

 

i)           General
Solicitation. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or any other general solicitation or general advertisement.

 

j)           Acknowledgment
of Form 10-K Extension. The Purchaser understands, acknowledges and agrees that the Company has filed an extension for filing
of its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and will therefore not file such Annual Report on
Form 10-K for the fiscal year ended December 31, 2016 until on or before April 14, 2017.

 

k)          Short
Sales and Confidentiality Prior To The Date Hereof. Other than consummating the transactions contemplated hereunder, such Purchaser
has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, executed
any purchases or sales, including Short Sales, of the securities of the Company during the period commencing from the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder until the date hereof (“Discussion Time”).
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement, such Purchaser has maintained
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this
transaction). “Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under
the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

    	 	4	 

     

    

 

3.          Representations
and Warranties of the Company. The Company represents and warrants to the Purchaser, as of the date hereof and the Closing
Date, that:

 

a)          Organization
and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate
and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
and conducted. Schedule 3(a) sets forth a list of all of the Subsidiaries of the Company and the jurisdiction in which each is
incorporated. The Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business and is in good
standing in every jurisdiction in which its ownership or use of property or the nature of the business conducted by it makes such
qualification necessary except where the failure to be so qualified or in good standing would not have a Material Adverse Effect.
“Material Adverse Effect” means any material adverse effect on the business, operations, assets, financial condition
or prospects of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the
agreements or instruments to be entered into in connection herewith. “Subsidiaries” means any corporation or other
organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership
interest.

 

b)          Authorization;
Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement and the
Note and Warrant and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance
with the terms hereof and thereof, (ii) the execution and delivery of this Agreement and the Note and Warrant by the Company and
the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note
and Warrant and the issuance and reservation for issuance of the Conversion Shares and Warrant Shares issuable upon conversion
and exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization
of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered
by the Company by its authorized representative, and such authorized representative is the true and official representative with
authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and
(iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note and Warrant each of such instruments
will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

    	 	5	 

     

    

 

c)          Capitalization.
As of the date hereof, the authorized capital stock of the Company, and number of shares issued and outstanding, is as set forth
in the Company’s most recent periodic report filed with the SEC. Except as disclosed in the Company’s SEC Documents,
no shares are reserved for issuance pursuant to the Company’s stock option plans. Except as disclosed in the SEC Documents
no shares are reserved for issuance pursuant to securities exercisable for, or convertible into or exchangeable for shares of Common
Stock. All of such outstanding shares of capital stock are duly authorized, validly issued, fully paid and non-assessable. No shares
of capital stock of the Company are subject to preemptive rights or any other similar rights of the shareholders of the Company
or any liens or encumbrances imposed through the actions or failure to act of the Company. As of the date of this Agreement, and
except as disclosed in the SEC Documents (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts,
calls, rights of first refusal, agreements, understandings, claims or other commitments or rights of any character whatsoever relating
to, or securities, notes or rights convertible into or exchangeable for any shares of capital stock of the Company or any of its
Subsidiaries, or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares
of capital stock of the Company or any of its Subsidiaries, (ii) there are no agreements or arrangements under which the Company
or any of its Subsidiaries is obligated to register the sale of any of its or their securities under the 1933 Act and (iii) there
are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement providing
rights to security holders) that will be triggered by the issuance of any of the Securities. The SEC Documents contain true and
correct copies of the Company’s Certificate of Incorporation as in effect on the date hereof (“Certificate of Incorporation”),
the Company’s By-laws, as in effect on the date hereof (the “By-laws”), and a description of the terms of all
securities convertible into or exercisable for Common Stock of the Company and the material rights of the holders thereof in respect
thereto.

 

d)          Issuance
of Shares. The Conversion Shares and Warrant Shares are duly authorized and reserved for issuance and, when issued and paid
for upon conversion of the Note and exercise of the Warrant, as the case may be, in accordance with their respective terms, will
be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue
thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose
personal liability upon the holder thereof.

 

e)          Acknowledgment
of Dilution. The Company’s executive officers and directors understand the nature of the Securities being sold hereby
and recognize that the issuance of the Securities will have a potential dilutive effect on the equity holdings of other holders
of the Company’s equity or rights to receive equity of the Company.  The board of directors of the Company has
concluded, in its good faith business judgment that the issuance of the Securities is in the best interests of the Company.  The
Company specifically acknowledges that its obligation to issue the Conversion Shares upon conversion of the Notes and the Warrant
Shares upon exercise of the Warrants is binding upon the Company and enforceable regardless of the dilution such issuance may have
on the ownership interests of other stockholders of the Company or parties entitled to receive equity of the Company.

 

    	 	6	 

     

    

 

f)           No
Conflicts. The execution, delivery and performance of this Agreement, the Note and the Warrant by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation
for issuance of the Conversion Shares and Warrant Shares) will not (i) conflict with or result in a violation of any provision
of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or
constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument
to which the Company or any of its Subsidiaries is a party and that is not filed as an SEC Document or other document filed with
the SEC, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation
of its Certificate of Incorporation, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries
is in default (and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries
in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to
which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries
is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect.
The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the
Purchaser owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. Except as specifically
contemplated by this Agreement and as required under the applicable listing requirements under NASDAQ and under the 1933 Act and
any applicable state securities laws, the Company is not required to obtain any consent, authorization or order of, or make any
filing or registration with, any court, governmental agency, regulatory agency, self-regulatory organization or stock market or
any third party in order for it to execute, deliver or perform any of its obligations under this Agreement and the Note and Warrant
in accordance with the terms hereof or thereof or to issue and sell the Securities in accordance with the terms hereof and thereof
and to issue the Conversion Shares and Warrants Shares. All consents, authorizations, orders, filings and registrations which the
Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof.
The Company is not in violation of the listing requirements of Nasdaq except as set forth in public disclosures by the Company,
and the Company shall cure such violations within the time period provided Nasdaq.

 

    	 	7	 

     

    

 

g)          SEC
Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by it with the SEC , for the two years preceding the date hereof (or such shorter period as the Company was required
by law or regulation to file such material) (all of the foregoing filed prior to the date hereof and all exhibits included therein
and financial statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference
therein, being hereinafter referred to herein as the “SEC Documents”). As of their respective dates, the SEC Documents
complied in all material respects with the requirements of the Securities Exchange Act of 1934, as amended (“1934 Act”
or “Exchange Act”), and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. None of the statements made in any such SEC
Documents is required to be amended or updated under applicable law (except for such statements as have been amended or updated
in subsequent filings prior the date hereof). As of their respective dates, the financial statements of the Company included in
the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules
and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with United States
generally accepted accounting principles (“GAAP”), consistently applied, during the periods involved and fairly present
in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof
and the consolidated results of their operations and cash flows for the periods then ended (except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as set forth
in the financial statements of the Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise,
other than (i) liabilities incurred in the ordinary course of business, and (ii) obligations under contracts and commitments incurred
in the ordinary course of business and not required under generally accepted accounting principles to be reflected in such financial
statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.
The Company is subject to the reporting requirements of the 1934 Act.

 

h)          Absence
of Certain Changes. Since December 31, 2015, there has been no material adverse change and no material adverse development
in the assets, liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act
reporting status of the Company or any of its Subsidiaries, except as disclosed in the SEC Documents.

 

i)           Absence
of Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such,
that could have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances which might
give rise to any of the foregoing.

 

j)           Patents,
Copyrights, Etc. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to use all patents,
patent applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications, service marks, service
names, trade names and copyrights (“Intellectual Property”) necessary to enable it to conduct its business as now operated
(and, as presently contemplated to be operated in the future); to the best of the Company’s knowledge, there is no claim
or action by any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened, which challenges
the right of the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable it to conduct its business
as now operated (and, as presently contemplated to be operated in the future); to the best of the Company’s knowledge, the
Company’s or its Subsidiaries’ current and intended products, services and processes do not infringe on any Intellectual
Property or other rights held by any person and/or entity; and the Company is unaware of any facts or circumstances which might
give rise to any of the foregoing. The Company and each of its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of their Intellectual Property.

 

    	 	8	 

     

    

 

k)          No
Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate or
other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers
has or is expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party
to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse
Effect.

 

l)           Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all
other tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent
that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all
unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set
aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such
returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has not executed a waiver
with respect to the statute of limitations relating to the assessment or collection of any foreign, federal, state or local tax.
None of the Company’s tax returns is presently being audited by any taxing authority.

 

m)          Certain
Transactions. Except as may be disclosed in the SEC Documents, for arm’s length transactions pursuant to which the Company
or any of its Subsidiaries makes payments in the ordinary course of business upon terms no less favorable than the Company or any
of its Subsidiaries could obtain from third parties, and other than the grant of any stock options disclosed in the SEC Documents,
none of the officers, directors, or employees of the Company is presently a party to any transaction with the Company or any of
its Subsidiaries (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge of the Company, any corporation, partnership, trust
or other entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee
or partner.

 

    	 	9	 

     

    

 

n)          Disclosure.
All information relating to or concerning the Company or any of its Subsidiaries set forth in this Agreement and provided to the
Purchaser pursuant to Section 2(d) hereof and otherwise in connection with the transactions contemplated hereby is true and correct
in all material respects and the Company has not omitted to state any material fact necessary in order to make the statements made
herein or therein, in light of the circumstances under which they were made, not misleading. No event or circumstance has occurred
or exists with respect to the Company or any of its Subsidiaries or its or their business, properties, prospects, operations or
financial conditions, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company
but which has not been so publicly announced or disclosed.

 

o)          Acknowledgment
Regarding Purchaser’ Purchase of Securities. The Company acknowledges and agrees that the Purchaser is acting solely
in the capacity of arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company
further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to this Agreement and the transactions contemplated hereby and any statement made by the Purchaser or any of its respective
representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation
and is merely incidental to the Purchaser’s purchase of the Securities.

 

p)          No
Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would
require registration under the 1933 Act of the issuance of the Securities to the Purchaser. The issuance of the Securities to the
Purchaser will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes
of any shareholder approval provisions applicable to the Company or its securities.

 

q)          Brokers.
The Company hereby represents and warrants that it has not hired, retained or dealt with any broker, finder, consultant, person,
firm or corporation in connection with the negotiation, execution or delivery of this Agreement or the transactions contemplated
hereunder. The Company covenants and agrees that should any claim be made against Purchaser for any commission or other compensation
by any broker, finder, person, firm or corporation based upon the Company’s engagement of such person in connection with
this transaction or such person introducing the parties hereto, the Company shall indemnify, defend and hold Purchaser harmless
from and against any and all damages, expenses (including attorneys’ fees and disbursements) and liability arising from such
claim.

 

r)           Permits;
Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses,
permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its
properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”), and there
is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of the Company
Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of the Company
Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not reasonably be
expected to have a Material Adverse Effect. Since December 31, 2015 neither the Company nor any of its Subsidiaries has received
any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices relating to
possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse Effect.

 

    	 	10	 

     

    

 

s)          Environmental
Matters.

 

i.           There
are, to the Company’s knowledge, with respect to the Company or any of its Subsidiaries or any predecessor of the Company,
no past or present violations of Environmental Laws (as defined below), releases of any material into the environment, actions,
activities, circumstances, conditions, events, incidents, or contractual obligations which may give rise to any common law environmental
liability or any liability under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 or similar federal,
state, local or foreign laws and neither the Company nor any of its Subsidiaries has received any notice with respect to any of
the foregoing, nor is any action pending or, to the Company’s knowledge, threatened in connection with any of the foregoing.
The term “Environmental Laws” means all federal, state, local or foreign laws relating to pollution or protection of
human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface
strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants
contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses,
notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

ii.          Other
than those that are or were stored, used or disposed of in compliance with applicable law, no Hazardous Materials are contained
on or about any real property currently owned, leased or used by the Company or any of its Subsidiaries, and no Hazardous Materials
were released on or about any real property previously owned, leased or used by the Company or any of its Subsidiaries during the
period the property was owned, leased or used by the Company or any of its Subsidiaries, except in the normal course of the Company’s
or any of its Subsidiaries’ business.

 

iii.         There
are no underground storage tanks on or under any real property owned, leased or used by the Company or any of its Subsidiaries
that are not in compliance with applicable law.

 

t)         Title
to Property. The Company and its Subsidiaries have good and marketable title in fee simple to all real property and good and
marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries,
in each case free and clear of all liens, encumbrances and defects except such as would not have a Material Adverse Effect. Any
real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as would not have a Material Adverse Effect.

 

    	 	11	 

     

    

 

u)          Insurance.
The Company and its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such coverage amounts as are prudent and customary in the businesses in which the Company is engaged, including, but not limited
to, directors and officers insurance coverage with coverage amounts that are at least equal to the aggregate Purchase Price. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.

 

v)          Internal
Accounting Controls. Except as disclosed in the SEC Documents, the Company and each of its Subsidiaries maintain a system of
internal accounting controls sufficient, in the judgment of the Company’s board of directors, to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or
specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences.

 

w)          Foreign
Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee or other person
acting on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the Company, used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; made
any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; violated
or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any bribe, rebate, payoff,
influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

 

x)          Solvency.
Except as disclosed in the SEC Documents, the Company (after giving effect to the transactions contemplated by this Agreement)
is solvent (i.e., its assets have a fair market value in excess of the amount required to pay its probable liabilities on
its existing debts as they become absolute and matured) and currently the Company has no information that would lead it to reasonably
conclude that the Company would not, after giving effect to the transaction contemplated by this Agreement, have the ability to,
nor does it intend to take any action that would impair its ability to, pay its debts from time to time incurred in connection
therewith as such debts mature.

 

y)          No
Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement
will not be, an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment
Company”). The Company is not controlled by an Investment Company.

 

z)          No “Shell”.
As of the date of this Agreement, either (i) the Company is not or has never been a “shell issuer” as defined in Rule
144 or (ii) at least 12 months have passed since the Company filed Form 10 Type information indicating it is not a “shell
issuer”.

 

    	 	12	 

     

    

 

aa)        Bad
Actor. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none
of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating
in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the
Company in any capacity at the time of sale (each, an "Issuer Covered Person" and, together, "Issuer Covered
Persons") is subject to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to (viii) under
the Securities Act (a "Disqualification Event"), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished
to the Purchasers a copy of any disclosures provided thereunder.

 

bb)        Clinical
Studies. The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or
in which the Company or products or product candidates have participated that are described in the SEC Documents were and, if still
pending, are being conducted in accordance in all material respects with all applicable federal, state or foreign statutes, laws,
rules and regulations, as applicable (including, without limitation, those administered by the Food and Drug Administration of
the U.S. Department of Health and Human Services (the “FDA”) or by any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA and current Good Laboratory and Good Clinical
Practices) and in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional
scientific methods. The descriptions in the SEC Documents of the results of such studies, tests and trials are accurate and complete
in all material respects and fairly present the published data derived from such studies, tests and trials. The Company has not
received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory
authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies
or tests requiring the termination, suspension or material modification of such studies, tests or preclinical or clinical trials,
which termination, suspension or material modification would reasonably be expected to result in a Material Adverse Effect. No
filing or submission to the FDA or any other federal, state or foreign regulatory body, that is intended to be the basis for any
approval, contains any material statement or material false information. The Company is in compliance with all applicable federal,
state, local and foreign laws, regulations, orders and decrees governing their business as prescribed by the FDA, or any other
federal, state or foreign agencies or bodies, including those bodies and agencies engaged in the regulation of pharmaceuticals
or biohazardous substances or materials, except where noncompliance would not, singly or in the aggregate, result in a Material
Adverse Effect.

 

4.          COVENANTS.

 

a)          Best
Efforts. The parties shall use their best efforts to satisfy timely each of the conditions described in Section 8 and 9 of
this Agreement.

 

    	 	13	 

     

    

 

b)          Form
D; Blue Sky Laws. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D
and to provide a copy thereof to the Purchaser promptly after such filing. The Company shall, on or before the Closing Date, take
such action as the Company shall reasonably determine is necessary to qualify the Securities for sale to the Purchaser at the applicable
closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States
(or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Purchaser on
or prior to the Closing Date.

 

c)          Use
of Proceeds. The Company shall use the proceeds from the sale of the Securities for general corporate purposes, research and
development, key personnel recruiting and business development purposes.

 

d)          Financial
Information. Upon written request of the Purchaser, the Company agrees to send or make available to the Purchaser contemporaneously
with the making available or giving to the shareholders of the Company, copies of any notices or other information the Company
makes available or gives to such shareholders. Notwithstanding the foregoing, the Company shall not disclose any material nonpublic
information to the Purchaser without its consent unless such information is disclosed to the public prior to or promptly following
such disclosure to the Purchaser.

 

e)          Listing.
The Company will obtain and, so long as the Purchaser owns any of the Securities, maintain the listing and trading of its Common
Stock on the NASDAQ Stock Market (“NASDAQ”), or the OTC QX Market (“OTCQX”), the New York Stock Exchange
(“NYSE”), or the NYSE MKT, f/k/a American Stock Exchange (“AMEX”), and will comply in all respects with
the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory Authority
(“FINRA”) and such exchanges, as applicable. The Company shall promptly provide to the Purchaser copies of any notices
it receives from the SEC, NASDAQ, OTCQX and any other exchanges or quotation systems on which the Common Stock is then listed regarding
the continued eligibility of the Common Stock for listing on such exchanges and quotation systems, provided that it shall not provide
any notices constituting material nonpublic information. If the transactions contemplated hereby are not approved by NASDAQ within
30 days following the date hereof, then within three (3) days following the earlier of the completion of such 30 day period or
any rejection by NASDAQ, the Company shall redeem the Note for a redemption price equal to the Purchase Price (i.e., the Company
shall return all funds received by it from the Purchaser).

 

f)           Corporate
Existence. So long as the Purchaser beneficially owns any Securities, the Company shall maintain its corporate existence and
shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale
of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes
the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith and (ii)
is a publicly traded corporation whose Common Stock is listed for trading on NASDAQ, NYSE, AMEX or OTCQX.

 

    	 	14	 

     

    

 

g)          No
Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances
that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the
Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision
applicable to the Company or its securities.

 

h)          Securities
Laws Disclosure; Publicity. The Company shall comply with applicable securities laws by filing a Current Report on Form 8-K,
within four (4) Trading Days following the date hereof, disclosing all the material terms of the transactions contemplated hereby,
if the Company deems the transactions contemplated hereby to constitute material non-public information. The Company and Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither
the Company nor Purchaser shall issue any such press release or otherwise make any such public statement without the prior consent
of the Company, with respect to any press release of any Purchaser, or without the prior consent of Purchaser, with respect to
any press release of the Company, except if such disclosure is required by law, in which case the disclosing party shall promptly
provide the other party with prior notice of such public statement or communication.

 

i)           Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the
Company covenants and agrees that neither it nor any other person acting on its behalf will provide the Purchaser or its agents
or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto the
Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands
and confirms that the Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

j)           Subsidiaries.
So long as the Note remains outstanding, the Company shall not transfer any assets or rights to any of its subsidiaries or permit
any of its subsidiaries to engage in any significant business or operations, whether such subsidiaries are currently existing or
hereafter created, except that to the extent that the Company desires to effect a spin-off distribution, the Purchaser’s
consent to same shall not be unreasonably withheld provided that the Company and the entities which are the subject of such spin-off
enter into such documentation reasonably acceptable to the Purchaser to provide for the Purchaser to receive substantially the
same economic benefit as contemplated hereunder.

 

k)          Insurance.
So long as the Note remains outstanding, the Company and its Subsidiaries shall maintain in full force and effect insurance reasonably
believed by the Company to be adequate coverage (a) on all assets and activities, covering property loss or damage and loss of
income by fire or other hazards or casualty, and (b) against all liabilities, claims and risks for which it is customary for companies
similarly situated to the Company to insure, including without limitation applicable product liability insurance, required workmen’s
compensation insurance, and other insurance covering injury or damage to persons or property, but excluding directors and officers
insurance coverage. The Company shall promptly furnish or cause to be furnished evidence of such insurance to the Purchaser, in
form and substance reasonably satisfactory to the Purchaser.

 

    	 	15	 

     

    

 

l)           ROFR.
In the event that at any time on or prior to the date which is six months following the Closing Date, the Company desires to raise
additional capital in a transaction which involves the sale or issuance of convertible securities (a “Prospective Financing”),
in whole or in part, the Purchaser shall have the right of first refusal to participate in the Prospective Financing, and the Company
shall provide written notice containing the terms of such Prospective Financing (the “ROFR Notice”) to the Purchaser
prior to effectuating any such transaction. The ROFR Notice shall specify all of the key terms of the Prospective Financing, including,
but not limited to, the proposed investment amount, the proposed rate of interest, the proposed conversion price, the proposed
term of the investment, the type and number of securities to be sold and any and all other relevant terms, each as applicable.
Except as otherwise provided below, upon Purchaser’s receipt of the ROFR Notice, Purchaser shall have the exclusive right
to participate in such Prospective Financing(s), upon the terms specified in the ROFR Notice, by sending written notice to the
Company within seven (7) business days after Purchaser’s receipt of the ROFR Notice. In the event Purchaser fails to exercise
its right of first refusal with respect to an ROFR Notice within the time set forth above, Purchaser shall be deemed to have waived
its right of first refusal with respect to such Prospective Financing, provided that it shall retain such right with respect to
any future Prospective Financing. In the event that a Prospective Financing is in the form of a shelf-take down (a “Shelf
Offering”), the Company shall provide the Purchaser with a ROFR Notice no later than the same day of the proposed Shelf
Offering. The ROFR Financing Notice shall describe in reasonable detail the proposed terms of such Shelf Offering, the amount of
proceeds intended to be raised thereunder and the Person or Persons through or with whom such Shelf Offering is proposed to be
effected and shall include a term sheet or similar document relating thereto as an attachment. Should the Purchase desire to participate
in such Shelf Offering it must provide a written notice to the Company, by no later than four (4) hours after the Purchaser has
received the ROFR Notice, that it is willing to participate in the Prospective Financing, the amount of the Purchaser’s participation,
and representing and warranting that the Purchaser has such funds ready, willing, and available for investment on the terms set
forth in the ROFR Financing Notice. Notwithstanding anything contained herein, the Company shall not furnish any material non-public
information concerning the Company without the Purchaser’s prior written consent, and shall initially only indicate to the
Purchaser that the Company contemplates a financing. Notwithstanding anything contained herein, in no event shall the Purchaser
be entitled to purchase any securities which would cause the sum of (1) the number of shares of Common Stock beneficially owned
by the Purchaser and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership
of the unconverted portion of the Note or the unexercised or unconverted portion of any other security of the Company subject to
a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of directly
or indirectly purchasable under this Section, to exceed 4.9% of the outstanding shares of Common Stock.

 

    	 	16	 

     

    

 

m)         Future
Financings. From the date hereof until such time as the Purchaser no longer holds any of the Securities, in the event the Company
issues or sells any shares of Common Stock or securities directly or indirectly convertible into or exercisable for Common Stock
(“Common Stock Equivalents”) or amends the transaction documents relating to any sale or issuance of Common Stock or
Common Stock Equivalents, if the Purchaser reasonably believes that the terms and conditions thereunder are more favorable to such
investors as the terms and conditions granted under this Agreement and the transactions contemplated hereby, upon notice to the
Company by such Purchaser, this Agreement and the transaction documents entered into in connection herewith shall be deemed automatically
amended so as to give the Purchaser the benefit of such more favorable terms or conditions. The Company shall deliver acknowledgment
of such automatic amendment to such transaction documents to the Purchaser in form and substance reasonably satisfactory to the
Purchaser (the “Acknowledgment”) within three (3) business days of Company’s receipt of request from Purchaser
(the “Deadline”), provided that Company’s failure to timely provide the Acknowledgement shall not affect the
automatic amendments contemplated hereby.

 

n)          Stockholder
Approval. If on any date following the Closing Date (the “Stockholder Approval Triggering Date”) the sum of (i)
the number of Conversion Shares and Warrant Shares previously issued by the Company, plus (ii) the remaining number of Conversion
Shares and Warrant Shares issuable under the Note and Warrant (without regard to any limitations on beneficial ownership or on
the amount which may be converted, exercised or exchanged) is greater than seventy-five percent (75%) of the Maximum Share Issuance
(as defined in the Note), then the Company shall hold a meeting of the Company’s stockholders (“Stockholder Meeting)
at the earliest practical date after the Stockholder Approval Triggering Date and shall propose and solicit a vote of or written
consent by the requisite number of stockholders of the Company under applicable corporate law, in accordance with the Company’s
Certificate of Incorporation and By-Laws, and in accordance with the applicable rules and regulations of Nasdaq and the SEC, which
approves the transactions contemplated hereby, including the issuance of any and all Conversion Shares and Warrant Shares equal
to and in excess of twenty percent (20%) of the Common Stock and voting power of the Company outstanding before the Closing Date
(“Stockholder Approval”). Within thirty (30) days following the Stockholder Approval Triggering Date, the Company shall
file with the SEC and deliver to its stockholders a notice of meeting and proxy statement or information circular, as required
by the SEC, with respect to such Stockholder Meeting which contains a proposal seeking Stockholder Approval. Such Stockholder Meeting
shall occur within sixty (60) days following the filing of such proxy statement or information circular. The Board of Directors
of the Company shall recommend to the Company’s stockholders that such proposal be approved, which recommendation shall be
contained in such proxy statement or information circular, and the Company shall solicit proxies from its stockholders in connection
therewith in the same manner as all other management proposals in such proxy statement (or as typically solicited by management
for management proposals), and all management-appointed proxy holders shall vote their proxies in favor of such Stockholder Approval.
The Purchaser and its counsel shall be entitled to review such proxy statement or information circular prior to filing with the
SEC, and such proxy statement or information circular shall not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company does not obtain Stockholder Approval at the first such Stockholder Meeting,
the Company shall call a Stockholder Meeting every four months thereafter to seek Stockholder Approval until the earlier of the
date on which Stockholder Approval is obtained or no Securities remain outstanding. If the Company fails to (i) file the proxy
statement or information circular referred to above or (ii) hold the Stockholder Meeting referred to above, in each case prior
to the date by which such filing or meeting is required above, then such failure shall constitute an Event of Default under the
Note, and the Purchaser shall have the right to compel the Company to redeem the Warrant at the value of such Warrant determined
using the Black-Scholes Option Pricing Model via Bloomberg, provided that such Warrant valuation shall not exceed $250,000.

 

    	 	17	 

     

    

 

o)          Escrow.
If at any time while the Note is outstanding the Company raises additional capital through one or more financings, the Company
shall cause 50% of the proceeds thereof to be placed in escrow with the Company’s counsel on terms and conditions reasonably
acceptable to the Purchaser, up to an aggregate escrow amount of at least 200% of the outstanding face amount of the Note. Such
proceeds placed in escrow (a) shall be held in escrow solely for the purpose of repaying the Note, whether upon maturity, acceleration,
redemption or otherwise, and (b) may be removed from escrow and returned to the Company to the extent the amount held therein exceeds
200% of the then outstanding face amount of the Note due to repayments or conversions.

 

5.          Transfer
Agent Instructions. Upon receipt of a duly executed Notice of Conversion, the Company shall issue irrevocable instructions
to its transfer agent to issue certificates, registered in the name of the Purchaser or its nominee, for the Conversion Shares
in such amounts as specified from time to time by the Purchaser to the Company upon conversion of the Note, or any part thereof,
in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”). In the event that the Company
proposes to replace its transfer agent, the Company shall provide, prior to the effective date of such replacement, a fully executed
Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to this Agreement and the Securities (including
but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount (as defined in the Note))
signed by the successor transfer agent to Company and the Company. Prior to registration of the Conversion Shares under the 1933
Act or the date on which the Conversion Shares may be sold pursuant to Rule 144 without any restriction as to the number of Securities
as of a particular date that can then be immediately sold, all such certificates shall bear the restrictive legend specified in
Section 2(g) of this Agreement. The Company agrees that: (i) no instruction other than the Irrevocable Transfer Agent Instructions
referred to in this Section 5, and stop transfer instructions to give effect to Section 2(f) hereof (in the case of the Conversion
Shares, prior to registration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold
pursuant to Rule 144 without any volume restrictions), will be given by the Company to its transfer agent, and the Securities shall
otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the
Note; (ii) it will not direct its transfer agent to prevent or delay, or impair or hinder its transfer agent in, transferring (or
issuing)(electronically or in certificated form) any certificate for Conversion Shares or Warrant Shares to be issued to the Purchaser
upon conversion or exercise of or otherwise pursuant to the Note or Warrant as and when required by the Note, Warrant and this
Agreement; and (iii) it will not fail to remove (or direct its transfer agent not to remove or impair, delay, and/or hinder its
transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any
certificate for any Conversion Shares or Warrant Shares issued to the Purchaser upon conversion or exercise of or otherwise pursuant
to the Note or Warrant as and when required by the Note, the Warrant or this Agreement. Nothing in this Section shall affect in
any way the Purchaser’s obligations and agreement set forth in Section 2(g) hereof to comply with all applicable prospectus
delivery requirements, if any, upon re-sale of the Securities, or the Purchaser’s obligations to comply with the provisions
of Rule 144, as applicable. If the Purchaser provides the Company with (i) an opinion of counsel in form, substance and scope customary
for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration
under the 1933 Act and such sale or transfer is effected or (ii) the Purchaser provides reasonable assurances that the Securities
can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in the case of the Conversion Shares or Warrant Shares,
promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such
denominations as specified by the Purchaser. The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Purchaser, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the
Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 may be inadequate and agrees,
in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Purchaser shall be entitled,
in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without
the necessity of showing economic loss and without any bond or other security being required.

 

    	 	18	 

     

    

 

6.          Injunction Posting
of Bond.  In the event the Purchaser shall elect to convert the Note or exercise the Warrant or any parts thereof,
the Company may not refuse conversion or exercise based on any claim that Purchaser or anyone associated or affiliated with Purchaser
has been engaged in any violation of law, or for any other reason. In connection with any injunction sought or attempted by the
Company, the Company shall be required to post a bond at least equal to the greater of either: (i) the outstanding principal amount
of the Note; and (ii) the market value of the Conversion Shares and/or Warrant Shares sought to be converted, exercised or issued,
based on the sale price per share of Common Stock on the principal market on which it is traded.

 

7.          Delivery
of Unlegended Shares.

 

a)          Within
three (3) business days (such third business day being the “Unlegended Shares Delivery Date”) after the business
day on which the Company has received (i) a notice that Conversion Shares, or any other Common Stock held by the Purchaser has
been sold pursuant to a registration statement or Rule 144 under the 1933 Act, (ii) a representation that the prospectus delivery
requirements, or the requirements of Rule 144, as applicable and if required, have been satisfied, (iii) the original share certificates
representing the shares of Common Stock that have been sold, and (iv) in the case of sales under Rule 144, customary representation
letters of the Purchaser and, if required, Purchaser’s broker regarding compliance with the requirements of Rule 144, the
Company at its expense, (y) shall deliver, and shall cause legal counsel selected by the Company to deliver to its transfer agent
(with copies to Purchaser) an appropriate instruction and opinion of such counsel, directing the delivery of shares of Common Stock
without any legends including the legend set forth herein (the “Unlegended Shares”); and (z) cause the transmission
of the certificates representing the Unlegended Shares together with a legended certificate representing the balance of the submitted
Common Stock certificate, if any, to the Purchaser at the address specified in the notice of sale, via express courier, by electronic
transfer or otherwise on or before the Unlegended Shares Delivery Date.

 

    	 	19	 

     

    

 

b)          The Company
understands that a delay in the delivery of the Unlegended Shares later than the Unlegended Shares Delivery Date could result in
economic loss to the Purchaser. As compensation to Purchaser for such loss, the Company agrees to pay late payment fees (as liquidated
damages and not as a penalty) to the Purchaser for late delivery of Unlegended Shares in the amount of $1,000.00 per business day
after the Unlegended Shares Delivery Date. If during any three hundred and sixty (360) day period, the Company fails to deliver
Unlegended Shares as required by this Section for an aggregate of thirty (30) days, then Purchaser or assignee holding Securities
subject to such default may, at its option, require the Company to redeem all or any portion of the shares subject to such default
at a price per share equal to the greater of (i) 200% of the most recent closing price of the Common Stock or (ii) a fraction in
which the numerator is the highest closing price of the Common Stock during the aforedescribed thirty (30) day period and the denominator
of which is the lowest conversion price during such thirty (30) day period, multiplied by the conversion price or exercise price,
as the case may be (“Unlegended Redemption Amount”). The Company shall pay any payments incurred under this
Section in immediately available funds upon demand.

 

8.          Conditions
to the Company’s Obligation to Sell. The obligation of the Company hereunder to issue and sell the Note and Warrant to
the Purchaser at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions
thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in
its sole discretion:

 

a)          The Purchaser shall
have executed this Agreement and delivered the same to the Company.

 

b)          The Purchaser shall
have delivered the Purchase Price to the Company.

 

c)          The representations
and warranties of the Purchaser shall be true and correct in all material respects as of the date when made and as of the Closing
Date as though made at that time (except for representations and warranties that speak as of a specific date), and the Purchaser
shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date.

 

d)          No litigation,
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over
the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

    	 	20	 

     

    

 

9.          Conditions
to The Purchaser’s Obligation to Purchase. The obligation of the Purchaser hereunder to purchase the Note and Warrant
at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that
these conditions are for the Purchaser’s sole benefit and may be waived by the Purchaser at any time in its sole discretion:

 

a)          The Company
shall have executed this Agreement and a registration rights agreement in the form of Exhibit C attached hereto (“Registration
Rights Agreement”) and delivered each of the same to the Purchaser.

 

b)          The Company
shall have delivered to the Purchaser the duly executed Note and Warrant (in such denominations as the Purchaser shall request)
in accordance with Section 1 above.

 

c)          The Irrevocable
Transfer Agent Instructions, in form and substance satisfactory to the Purchaser, shall have been delivered to and acknowledged
in writing by the Company’s Transfer Agent (a copy of which written acknowledgment shall be provided to Purchaser simultaneously
with Closing).

 

d)          The representations
and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing
Date as though made at such time (except for representations and warranties that speak as of a specific date) and the Company shall
have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this
Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. The Purchaser shall have
received a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing Date, to
the foregoing effect and as to such other matters as may be reasonably requested by the Purchaser including, but not limited to
certificates with respect to the Company’s Certificate of Incorporation, By-laws, incumbency, and Board of Directors’
resolutions relating to the transactions contemplated hereby.

 

e)          No litigation,
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over
the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

f)           No
event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but not
limited to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act
reporting obligations.

 

g)          The Conversion
Shares shall have been authorized for quotation on the NASDAQ and trading of the Common Stock on the NASDAQ shall not have been
suspended by the SEC or the NASDAQ.

 

    	 	21	 

     

    

 

10.         Governing
Law; Miscellaneous.

 

a)          Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of
the State of New York without regard to principles of conflicts of laws thereof or any other State.  Any action brought
by any party against any other party hereto concerning the transactions contemplated by this Agreement shall be brought only in
the state courts of New York or in the federal courts located in the state and county of New York.  The parties to this
Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert
any defense based on lack of jurisdiction or venue or based upon forum non conveniens.  The parties executing
this Agreement and other agreements referred to herein or delivered in connection herewith on behalf of the Company agree to submit
to the in personam jurisdiction of such courts and hereby irrevocably waive trial by jury.  The prevailing party
shall be entitled to recover from the other party its reasonable attorney’s fees and costs.  In the event that
any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable
statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall
be deemed modified to conform with such statute or rule of law.  Any such provision which may prove invalid or unenforceable
under any law shall not affect the validity or enforceability of any other provision of any agreement.  Each party hereto
hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in
connection with this Agreement or any other transaction document contemplated hereby by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

b)          Removal
of Restrictive Legends.  In the event that Purchaser has any shares of the Company’s Common Stock bearing any
restrictive legends, and Purchaser, through its counsel or other representatives, submits to the Transfer Agent any such shares
for the removal of the restrictive legends thereon in connection with a sale of such shares pursuant to any exemption
to the registration requirements under the Securities Act, and the Company and or its counsel refuses or fails for any reason (except
to the extent that such refusal or failure is based solely on applicable law that would prevent the removal of such restrictive
legends) to render an opinion of counsel or any other documents or certificates required for the removal of the restrictive legends,
then the Company hereby agrees and acknowledges that the Purchaser is hereby irrevocably and expressly authorized to have counsel
to the Purchaser render any and all opinions and other certificates or instruments which may be required for purposes of removing
such restrictive legends, and the Company hereby irrevocably authorizes and directs the Transfer Agent to, without any further
confirmation or instructions from the Company, issue any such shares without restrictive legends as instructed by the Purchaser,
and surrender to a common carrier for overnight delivery to the address as specified by the Purchaser, certificates, registered
in the name of the Purchaser or its designees, representing the shares of Common Stock to which the Purchaser is entitled, without
any restrictive legends and otherwise freely transferable on the books and records of the Company.

 

    	 	22	 

     

    

 

c)          Filing
Requirements. From the date of this Agreement until the Note is no longer outstanding, the Company will timely and voluntarily
comply with all reporting requirements that are applicable to an issuer with a class of shares registered pursuant to Section 12(g)
of the 1934 Act, whether or not the Company is then subject to such reporting requirements, and comply with all requirements related
to any registration statement filed pursuant to this Agreement. The Company will use reasonable efforts not to take any action
or file any document (whether or not permitted by the 1933 Act or the 1934 Act or the rules thereunder) to terminate or suspend
such registration or to terminate or suspend its reporting and filing obligations under said acts until the Note is no longer outstanding.
The Company will maintain the quotation or listing of its Common Stock on the NYSE, or NASDAQ Stock Market or the OTC QX Market
(whichever of the foregoing is at the time the principal trading exchange or market for the Common Stock (the “Principal
Market”), and will comply in all respects with the Company’s reporting, filing and other obligations under the
bylaws or rules of the Principal Market, as applicable. The Company will provide Purchaser with copies of all notices it receives
notifying the Company of the threatened and actual delisting of the Common Stock from any Principal Market.  As of the
date of this Agreement and the Closing Date, NASDAQ is the Principal Market. Until the Note is no longer outstanding, the Company
will continue the listing or quotation of the Common Stock on a Principal Market and will comply in all respects with the Company’s
reporting, filing and other obligations under the bylaws or rules of the Principal Market.

 

d)          144
Default. In the event commencing twelve (12) months after the Closing Date and ending twenty-four (24) months thereafter, the
Purchaser is not permitted to resell any of the Conversion Shares without any restrictive legend or if such sales are permitted
but subject to volume limitations or further restrictions on resale as a result of the unavailability to Purchaser of an effective
registration statement or Rule 144(b)(1)(i) under the 1933 Act or any successor rule (a “144 Default”), for
any reason except for Purchasers’ status as an Affiliate or “control person” of the Company, or as a result of
a change in current applicable securities laws, then the Company shall pay such Purchaser as liquidated damages and not as a penalty
an amount equal to two percent (2%) of the value of Conversion Shares (based on the closing sale of the Common Stock) subject to
such 144 Default during the pendency of the 144 Default of each thirty day period thereafter (or portion thereof) until the earlier
of (a) the date such 144 Default is cured and (b) such time as there are no longer restrictions on resale for the Purchasers to
transfer the Shares pursuant to Rule 144.

 

e)          Fees
and Expenses. On or prior to the Closing, the Company shall pay or reimburse to Purchaser a non-refundable, non-accountable
sum equal to $10,000.00 as and for the fees, costs and expenses (including without limitation legal fees and disbursements and
due diligence and administrative expenses) incurred by the Purchaser in connection with the Purchaser’s due diligence and
negotiation, preparation and execution of the transaction documents and consummation of the transactions contemplated hereby. The
Purchaser may withhold and offset the balance of such amount from the payment of its Purchase Price otherwise payable hereunder
at Closing, which offset shall constitute partial payment of such Purchase Price in an amount equal to such offset. Except as expressly
set forth in this Agreement or the Note to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery
and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied
in connection with the delivery of any Securities to the Purchaser.

 

    	 	23	 

     

    

 

f)          
Origination Fee. In connection with the transactions contemplated hereby, the Company agrees to pay the Purchaser an origination
fee equal to 5% of the original principal amount of Note issued by the Company hereunder, which amount shall be paid to the Purchaser
upon Closing by adding such amount to the principal amount of the Note.

 

g)          Usury.
To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim, and
will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any
time hereafter in force, in connection with any claim, action or proceeding that may be brought by the Purchaser in order to enforce
any right or remedy under the Note. Notwithstanding any provision to the contrary contained in herein or under the Note, it is
expressly agreed and provided that the total liability of the Company under the Note for payments in the nature of interest shall
not exceed the maximum lawful rate authorized under applicable law (the “Maximum Rate”), and, without limiting
the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums
in the nature of interest that the Company may be obligated to pay under the Note or herein exceed such Maximum Rate. It is agreed
that if the maximum contract rate of interest allowed by law and applicable to the Note is increased or decreased by statute or
any official governmental action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will be
the Maximum Rate applicable to the Note from the effective date forward, unless such application is precluded by applicable law.
If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to the Purchaser with respect
to indebtedness evidenced by the Note, such excess shall be applied by the Purchaser to the unpaid principal balance of any such
indebtedness or be refunded to the Company, the manner of handling such excess to be at the Purchaser’s election.

 

h)          Headings.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of,
this Agreement.

 

i)           Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

j)           Entire
Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company
nor the Purchaser makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this
Agreement may be waived or amended other than by an instrument in writing signed by the Purchaser.

 

    	 	24	 

     

    

 

k)          Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, email or facsimile, addressed as set forth below or to such other address as such party shall have
specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall
be deemed effective (a) upon hand delivery or delivery by facsimile or email, with accurate confirmation generated by the transmitting
facsimile machine or computer, at the address, email or number designated below (if delivered on a business day during normal business
hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business
day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur. The addresses for such communications shall be:

 

	Purchaser:	EMA Financial, LLC 
	 	40 Wall Street, Suite 1700
	 	New York, NY 10005
	 	Attn: Felicia Preston
	 	admin@emafin.com
	 	 
	Company:	Immune Pharmaceuticals, Inc.
	 	430 East 29th Street, Suite 940
	 	New York, NY 10016
	 	Attn: Dr. Daniel Teper
	 	Email: Daniel.teper@immunepharma.com
	 	Fax: ________________

 

Each party
shall provide notice to the other party of any change in address.

 

l)           Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor the Purchaser shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other. Notwithstanding the foregoing, subject to Section 2(f), the Purchaser may assign its rights hereunder to
any person that purchases Securities in a private transaction from the Purchaser or to any of its “affiliates,” as
that term is defined under the 1934 Act, without the consent of the Company.

 

m)         Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

    	 	25	 

     

    

 

n)          Survival.
The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the
closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Purchaser. The Company agrees
to indemnify and hold harmless the Purchaser and all their officers, directors, employees and agents for loss or damage arising
as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants
set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as
they are incurred.

 

o)          Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

p)          No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

q)          Remedies.
The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Purchaser by vitiating
the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for
a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by
the Company of the provisions of this Agreement, that the Purchaser shall be entitled, in addition to all other available remedies
at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing
or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing
economic loss and without any bond or other security being required.

 

r)           Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be
an original and all of which together shall be deemed to be one and the same agreement.

 

s)          Signatures.
Any signature transmitted by facsimile, e-mail, or other electronic means shall be deemed to be an original signature.

 

(Remainder of page intentionally left blank)

 

IN WITNESS WHEREOF, the undersigned Purchaser
and the Company have caused this Agreement to be duly executed as of the date first above written.

 

	IMMUNE PHARMACEUTICALS, INC.	 
	 	 	 
	By:	 	 
	 	Name: 	 
	 	Title: 	 

 

	EMA FINANCIAL, LLC	 
	 	 	 
	By:	 	 
	Name:	Felicia Preston	 
	Title:	Director	 

 

    	 	26	 

     

    

 

GUARANTY

 

Each of the undersigned subsidiaries of the
Company jointly and severally, absolutely, unconditionally and irrevocably, guarantees to the Purchaser and their respective successors,
indorsees, transferees and assigns, the prompt and complete payment and performance by the Company when due (whether at the stated
maturity, by acceleration or otherwise) of all amounts due under, and all other obligations under, the Note. Each such subsidiary’s
liability under this Guaranty shall be unlimited, open and continuous for so long as this Guaranty remains in force.

 

	IMMUNE
    PHARMACEUTICALS LTD.	 	CYTOVIA,
    INC.
	 	 	 	 	 
	By:	 	 	By:	 
	Print
    Name/Title:	 	Print
    Name/Title:
	 	 	 	 	 
	MAXIM
    PHARMACEUTICALS, INC. 	 	IMMUNE
    PHARMACEUTICALS CORP 
	 	 	 	 	 
	By:	 	 	By:	 
	Print
    Name/Title:	 	Print
    Name/Title:

 

    	 	27	 

     

    

 

Schedule 3(A)

 

Immune Pharmaceuticals Ltd.

Cytovia, Inc. (DE)

Maxim Pharmaceuticals, Inc. (DE)

Immune Pharmaceuticals Corp

 

    	 	28	 

     

    

 

EXHIBIT A

 

Form of Note

 

    	 	29	 

     

    

 

EXHIBIT B

 

Form of Warrant

 

    	 	30	 

     

    

 

EXHIBIT C

 

Registration Rights Agreement

 

    	 	31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]